dipyridamole has been researched along with Pheochromocytoma, Extra-Adrenal in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roskoski, R | 1 |
| Roskoski, LM | 1 |
1 other study available for dipyridamole and Pheochromocytoma, Extra-Adrenal
| Article | Year |
|---|---|
Adenosine receptor activation and the regulation of tyrosine hydroxylase activity in PC12 and PC18 cells.
Topics: Adenine Nucleotides; Adenosine; Adenosine Deaminase; Adenosine Triphosphate; Adrenal Gland Neoplasms | 1989 |